Humm Group Ltd
Humm Group Ltd operates as a consumer finance provider, generating revenue through interest and fees on consumer credit products.
Business. Humm Group Ltd (HUM.AX) is a healthcare services and equipment company headquartered in Australia. The firm is primarily listed on the Australian Securities Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
- Congressional trades
- CongressLisa McClain — Humana Inc. Common Stock2025-10-31 · Republican · MI · Sale · $1,001 - $15,000
- CongressLisa McClain — Humana Inc. Common Stock2025-10-30 · Republican · MI · Purchase · $1,001 - $15,000
- CongressLisa McClain — Humana Inc. Common Stock2025-10-30 · Republican · MI · Sale · $1,001 - $15,000
- CongressLisa McClain — Humana Inc. Common Stock2025-09-25 · Republican · MI · Purchase · $1,001 - $15,000
- CongressLisa McClain — Humana Inc. Common Stock2025-06-24 · Republican · MI · Purchase · $1,001 - $15,000
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Humm Group Ltd (HUM.AX) is a healthcare services and equipment company headquartered in Australia. The firm is primarily listed on the Australian Securities Exchange. Specific details regarding its operating segments and geographic revenue mix are not available.
Humm Group Ltd maintains a highly leveraged capital structure, with total liabilities of 4.84 billion AUD against total equity of 503.2 million AUD, resulting in a debt-to-equity ratio of 9.3. The company holds 4.68 billion AUD in long-term debt, which significantly exceeds its total assets of 5.34 billion AUD. Despite this leverage, the firm generates 179 million AUD in operating cash flow, though free cash flow is constrained to 12.2 million AUD after 21.3 million AUD in capital expenditures. The market values the equity at 227 million AUD, implying a price-to-book ratio of 0.45, suggesting the market prices the equity at a steep discount to its book value.
Profitability metrics indicate modest returns on capital. The company reports a net income of 39.6 million AUD on revenue of 666.6 million AUD, yielding a net margin of approximately 5.9%. Return on equity stands at 7.87%, while return on assets is 0.74%. The operating income of 49.5 million AUD reflects an operating margin of roughly 7.4%. The gross profit of 330.5 million AUD suggests significant cost of goods sold or interest expense deductions before operating leverage is fully realized.
Revenue concentration and segment details are not explicitly provided in the available data, limiting the ability to assess specific product or geographic exposure. The company’s total revenue of 666.6 million AUD serves as the primary top-line metric, with no further breakdown of segment contributions or regional splits available for analysis.
Growth trajectory analysis is limited by the absence of historical period data in the current input. Without prior year or quarterly comparisons, year-over-year revenue or earnings growth rates cannot be calculated. The current snapshot provides a static view of the financial position, precluding trend analysis of revenue expansion or contraction.
Risk assessment highlights medium liquidity risk and low dilution risk. A key flag notes that net cash is negative after subtracting total debt, emphasizing the reliance on debt financing. The high debt-to-equity ratio of 9.3 amplifies financial risk, particularly in rising interest rate environments. The low dilution risk suggests that share count stability is maintained, with basic and diluted shares outstanding both at 504.4 million.
Recent observations indicate strong analyst sentiment, with a mean recommendation of 1.50 (strong buy) and a mean price target of 0.80 AUD, significantly above the current market price of 0.45 AUD. The high price target of 0.85 AUD and low of 0.75 AUD suggest a consensus view of substantial upside potential. No specific filing, news, or transcript events are detailed in the available data to explain recent market movements or strategic shifts.
- The company trades at a significant discount to book value (P/B 0.45) despite high leverage (D/E 9.3).
- Analyst consensus suggests substantial upside, with a mean price target of 0.80 AUD versus the current 0.45 AUD.
- Free cash flow is thin at 12.2 million AUD, constrained by high capital expenditures relative to operating cash flow.
- Net income of 39.6 million AUD yields a modest ROE of 7.87%, reflecting the capital-intensive nature of consumer finance.
- Dilution risk is low, with no difference between basic and diluted share counts.
Bull / Bear case
Generated · model-assistedFY2025 net income surged 457.7% year-over-year to AUD 39.6 million, signaling a robust return to profitability.
Free cash flow turned positive in FY2025, reaching AUD 12.2 million after three years of negative generation.
Revenue grew at a 10.7% compound annual growth rate over the four-year period ending FY2025.
The company carries a high credit risk flag, indicating significant concerns regarding its debt servicing capabilities.
Debt-to-equity ratio of 9.3 places Humm in the bottom quartile of its peer cohort.
Return on equity of 7.9% falls below the cohort median of 11.3%, suggesting inefficient capital utilization.
Long-term debt increased to AUD 4.68 billion in FY2025, reflecting a heavy leverage burden.
Return on assets of 0.74% indicates minimal profitability relative to the total asset base employed.
In focus — financials by report
Revenue A$666.6M, +7,6% YoY; Operating income +503,7% YoY.
- ▍Revenue A$666.6M, +7,6% YoY
- ▍Operating income +503,7% YoY
- ▍Net income +457,8% YoY
- ▍Free cash flow +339,2% YoY
- ▍Net margin 5.9%
Revenue A$619.3M, +21,3% YoY; Operating income +925,0% YoY.
- ▍Revenue A$619.3M, +21,3% YoY
- ▍Operating income +925,0% YoY
- ▍Net income +144,8% YoY
- ▍Free cash flow +61,1% YoY
- ▍Net margin 1.1%
Revenue A$510.4M, +15,9% YoY; Operating income +100,4% YoY.
- ▍Revenue A$510.4M, +15,9% YoY
- ▍Operating income +100,4% YoY
- ▍Net income +101,7% YoY
- ▍Free cash flow +92,5% YoY
- ▍Net margin 0.6%
Revenue A$440.4M, −0,9% YoY; Operating income −324,4% YoY.
- ▍Revenue A$440.4M, −0,9% YoY
- ▍Operating income −324,4% YoY
- ▍Net income −383,4% YoY
- ▍Free cash flow −610,8% YoY
- ▍Net margin -38.7%
Revenue A$444.4M; Operating income A$81.9M.
- ▍Revenue A$444.4M
- ▍Operating income A$81.9M
- ▍Net margin 13.5%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 0,06 |
| Revenue | —no estimate | —no estimate | 640,0M AUD |
| Operating income | —no estimate | —no estimate | 18,2M AUD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director · Restricted Stock Units → Humana CommonAcquired 233grant · 2026-06-30
- Director · Restricted Stock Units → Humana CommonAcquired 536grant · 2026-03-31
- President, Insurance · Phantom Stock Units → Humana CommonAcquired 25other · 2026-03-31
- President & CEO · Restricted Stock Units → Humana CommonDisposed 2 183exercise · 2026-01-08
- Director · Restricted Stock Units → Humana CommonAcquired 766grant · 2026-01-02
- Director · Restricted Stock Units → Humana CommonAcquired 70grant · 2025-12-31
- Director · Restricted Stock Units → Humana CommonAcquired 35grant · 2025-12-31
- Director · Restricted Stock Units → Humana CommonAcquired 29grant · 2025-12-31
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Price To Tangible Bookmarket_price / (tangible_book_value / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Return On Equitynet_income / total_equity
- Enterprise Valuemarket_cap - net_cash
- Ev To Revenueenterprise_value / revenue
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Humm Group Ltd Market data — financials · 2026-07-27
- Humm Group Ltd Market data — analyst estimates · 2026-07-27
- Humm Group Ltd Market data — ESG · 2026-07-27
- Humana Inc — company reference export (2026-07-05) · 2026-07-27
Ownership & reference
Leadership
- Angelo DemasiChief Executive Officer, Executive Director
Insider activity
- President & CEO · Humana CommonOther 35 633 · 2026-05-01
- Chief Information Officer · Humana CommonOther 9 448 · 2026-05-01
- Chief Financial Officer · Humana CommonOther 15 387 · 2026-05-01
- President, Enterprise Growth · Humana CommonOther 11 273 · 2026-05-01
- Chief Human Resources Officer · Humana CommonOther 10 485 · 2026-05-01
- Director · Humana CommonOther 852 · 2026-05-01
- Chief Legal Officer · Humana CommonOther 10 318 · 2026-05-01
- President, CenterWell · Humana CommonOther 9 945 · 2026-05-01
- President, Medicare Advantage · Humana CommonOther 8 206 · 2026-05-01
- President, CenterWell · Humana CommonOther 887 · 2026-04-01
- President, CenterWell · Humana CommonOther 401 @ $175,44$70K · 2026-04-01
- SVP, Chief Accting Off & Cont. · Humana CommonOther 84 @ $177,07$15K · 2026-02-24
- SVP, Chief Accting Off & Cont. · Humana CommonOther 165 · 2026-02-24
- Chief Legal Officer · Humana CommonOther 1 035 · 2026-02-24
- President, Insurance · Humana CommonOther 1 035 · 2026-02-24
- Chief Legal Officer · Humana CommonOther 478 @ $177,07$85K · 2026-02-24
- President, Insurance · Humana CommonOther 419 @ $177,07$74K · 2026-02-24
- President, CenterWell · Humana CommonBought 810 @ $185,21$150K · 2026-02-23
- SVP, Chief Accting Off & Cont. · Humana CommonOther 5 669 · 2026-02-23
- President, Enterprise Growth · Humana CommonOther 1 182 @ $189,66$224K · 2026-02-21
- President, Enterprise Growth · Humana CommonOther 3 858 · 2026-02-21
- Chief Financial Officer · Humana CommonOther 7 763 · 2026-02-13
- Chief Financial Officer · Humana CommonOther 4 204 @ $181,46$763K · 2026-02-13
- Chief Information Officer · Humana CommonOther 430 @ $181,46$78K · 2026-02-13
- Chief Information Officer · Humana CommonOther 1 682 · 2026-02-13
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Current ratio (FY 2025-12-31): 2.00xDerived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 5.2%Derived (calculated)
- Return on equity (FY 2025-12-31): 6.7%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 7.8%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 10.1%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 5.5%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -68.9%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -1.6%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 11.0%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -1.4%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -1.4%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 89.1%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): -5.0%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 1.77xDerived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 3.8%Derived (calculated)
- Return on assets (FY 2025-12-31): 2.4%Derived (calculated)
- Net margin (FY 2025-12-31): 0.9%Derived (calculated)
- EPS (diluted) (annual): USD-PER-SHARES 10SEC XBRL filing
- Net income (annual): USD 1.19BSEC XBRL filing
- Revenue (annual): USD 129.66BSEC XBRL filing
- Current assets (annual): USD 32.73BSEC XBRL filing
- Cash & equivalents (annual): USD 4.2BSEC XBRL filing
- Total assets (annual): USD 48.91BSEC XBRL filing
- Current liabilities (annual): USD 16.35BSEC XBRL filing